Franco Maggiolo

机构：Ospedale Papa Giovanni XXIII · ORCID：0000-0002-9791-0072

发表论文 201 篇 · 总被引 4799 次 · h-index 35

代表论文

• A first update on mapping the human genetic architecture of COVID-19 (2022 · Nature · 被引 176)
• Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials (2023 · EClinicalMedicine · 被引 90)
• Pillars of long-term antiretroviral therapy success (2023 · Pharmacological Research · 被引 22)
• Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors (2024 · BMJ Open · 被引 21)
• Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy (2024 · AIDS · 被引 18)
• Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients (2022 · BMC Infectious Diseases · 被引 16)